EMBRACA Trial Compares Talazoparib Versus Standard Therapy in Advanced Breast Cancer With a Germline BRCA Mutation

As reported in The New England Journal of Medicine by Litton et al, the phase III EMBRACA trial has shown significantly improved progression-free survival with the poly (ADP-ribose) polymerase inhibitor talazoparib vs physician choice of standard single-agent therapy in patients with advanced breast cancer and a germline BRCA1 or BRCA2 mutation.

Early-Life Alcohol Intake May Increase the Odds of High-Grade Prostate Cancer Later in Life

Compared with nondrinkers, men who consumed at least 7 drinks per week during adolescence (ages 15-19) had 3 times the odds of being diagnosed with clinically significant prostate cancer, according to results published by Michael et al in Cancer Prevention Research.

Baseline Steroids and Efficacy of PD-1/PD-L1 Inhibitors in NSCLC

In a study reported in the Journal of Clinical Oncology, Arbour et al found that baseline treatment with corticosteroids was associated with poorer efficacy of programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors in patients with non-small-cell lung cancer (NSCLC).

US Preventive Services Task Force Recommendation Statement on Screening for Cervical Cancer

As reported in JAMA, the US Preventive Services Task Force has updated its 2012 recommendations on screening for cervical cancer.

Immunotherapy in Advanced Esophagogastric Cancer

As reported in the Journal of Clinical Oncology by Janjigian et al, the phase I/II CheckMate-032 study has shown activity of nivolumab and nivolumab plus ipilimumab in advanced esophagogastric cancer.

HPV Vaccine Completion Up 5% From 2016 to 2017

The number of adolescents who started and completed the human papillomavirus (HPV) vaccination increased 5 percentage points from 2016 to 2017, according to results from a national survey published by Walker et al in Morbidity and Mortality Weekly Report.

Immunotherapy Combination in Melanoma Brain Metastases

In a phase II study reported in The New England Journal of Medicine, Tawbi et al found that combined nivolumab and ipilimumab produced a high rate of intracranial clinical benefit in patients with melanoma brain metastases.

Tumor Mutation Burden and Prognosis in Resected NSCLC

In a study reported in the Journal of Clinical Oncology, Devarakonda et al found that high nonsynonymous tumor mutation burden was associated with improved outcomes in patients undergoing resection for non-small-cell lung cancer (NSCLC).

Sequential Liquid Biopsy Sampling May Be a Predictive Tool for Early Disease Progression in Patients With Colorectal Cancer

A prospective phase II study investigating the value of profiling subclonal mutations in the RAS pathway in the plasma cell-free DNA of patients with metastatic colorectal cancer to predict their response to anti-EGFR therapies has found that serial liquid biopsies, coupled with a mathematical framework of tumor evolution, could predict which patients are at risk for disease progression. The study by Khan et al was published in Cancer Discovery.

REFERENCES


November 1, 2018

Journal of Clinical Oncology, Vol 36, No 31 (November 1), 2018

Originally printed in The ASCO Post. © 2018 by Harborside Press